Medically reviewed by Matthew Wosnitzer, MD Key Takeaways Metastatic castration-resistant prostate cancer is an advanced form ...

Metastatic castration-resistant prostate cancer (mCRPC) is an advanced form of prostate cancer where the disease has spread beyond the prostate gland and no longer responds to conventional hormone ...

Androgen receptor (AR) gene dynamics in ctDNA post-abiraterone/enzalutamide: Longitudinal study in mCRPC with germline results. This is an ASCO Meeting Abstract from ...

Most prostate cancers become castration-resistant in about two to three years. Castration-resistant prostate cancer grows even when testosterone levels are low. Nonmetastatic castration-resistant ...

First-in-human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMA Preclinical presentation to ...

A paired spatial multi-omics study of prostate cancer reveals that rising cholesterol during therapy tracks with castration ...

NUCLIDIUM has entered a long-term partnership with NorthStar Medical to further bolster its radiopharmaceutical pipeline.

Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in differentiated targeted radiotherapies with the potential to transform cancer treatment, today announced ...

Reducing Fluorouracil Doses in Patients With Partial Dihydropyrimidine Dehydrogenase Deficiency Is a Treatment Safety Strategy, Not a Panacea of Precision Dosing As evidenced by the findings from ...

Clinical and pathologic characteristics of mCRPC were largely similar between younger and older patients. Overall survival was not significantly different between younger and older patients with mCRPC ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

According to the American Cancer Society, approximately 1 in 8 men in the U.S. will be diagnosed with prostate cancer during their lifetime. In addition, about 1 in 44 men will die from the disease, ...